The National Agency for Food and Drugs Administration and Control (NAFDAC) is notifying the public of the recall of two (2) lots of a hypertension drug, Cardura XL (Doxazosin) extended-release tablets (8mg & 4mg), manufactured by American global pharmaceutical and healthcare company, Viatris Inc., with lot numbers 81470418163765 and 81470408163764.
These drug lots are being recalled because they failed to meet impurity and degradation specifications.
Cardura XL (doxazosin mesylate) Extended-Release Tablets is an alpha-adrenergic blocker used to treat hypertension (high blood pressure) or to improve urination in men with benign prostatic hyperplasia (enlarged prostate).
Risk
The consequences of poor-quality drugs can include ineffective treatment, increased risk of adverse events, allergic reactions, anxiety, and general harm to patient and even death.
Product Details
The details of the affected product are as follows;
Product Name | Product Manufacturer | Batch No. |
Cardura XL (Doxazosin) | Viatris Inc. | 81470418163765 and 81470408163764 |
Product Photo
Viatris Inc. is the new company name following a merger of Pfizer’s Upjohn and Mylan.
NAFDAC implores importers, distributors, retailers and consumers to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the affected lots of the product. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Anyone in possession of the affected lots is advised to immediately discontinue sale or use and submit stock to the nearest NAFDAC office. If you have used this product, or someone you know, have used it, or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional.
Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322 or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med-safety application available for download on android and IOS stores or via e-mail on pharmacovigilance@nafdac.gov.ng
NAFDAC………. Customer-focused, Agency-minded!!!
